Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) is characterized by its inherent clinicopathological variability. The concurrence of upper and lower motor neuron signs is a common feature in the majority of patients with ALS. However, some patients manifest an atypical clinical course, with only upper or lower motor neuron signs, or various extra‐motor symptoms including cognitive dysfunction, parkinsonism, autonomic dysfunction, or ophthalmoparesis. This variability indicates different manifestations of ALS and is reflected by ALS pathology spreading into the central nervous system. The presence of cytoplasmic inclusions positive for transactivation response DNA‐binding protein 43 kDa (TDP‐43) is a key feature in ALS. Loss of TDP‐43 from the nucleus and its subsequent aggregation in the cytoplasm may occur in susceptible regions and may be associated with neuronal loss. However, in some regions, there is no apparent neuronal loss while TDP‐43 accumulation is evident; in contrast, in other regions, neuronal loss is apparent without any evidence of TDP‐43 accumulation. Therefore, in addition to TDP‐43 dysfunction, underlying region‐specific cellular vulnerability may exist in the upper and lower motor neurons and frontotemporal system in patients with ALS. The microscopic discrepancy and selective vulnerability may be linked to the macroscopic propensities of the sites of onset, and may also determine the direction and rate of progression of the lesions. Thus, there may be multicentric sites of onset, region‐oriented disease development, and different speeds of disease progression across patients with ALS. ALS lesions occur in motor‐related areas but may spread to neighboring areas. However, since lesions may spread in a discontinuous manner, and the dynamics of disease propagation have not been able to be identified, it remains controversial whether the stepwise appearance of TDP‐43‐positive inclusions is based on direct cell‐to‐cell protein propagation. Further understanding of the phenotypic variability of ALS and its pathological basis may serve as a guide for investigating the underlying pathogenesis of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis
Brettschneider, J., Del Tredici, K., Toledo, J. B., Robinson, J. L., Irwin, D. J., Grossman, M., Suh, E., Van Deerlin, V. M., Wood, E. M., Baek, Y., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23937 · Cited by 1,065
The central nervous system in motor neurone disease
Brownell, B., Oppenheimer, D. R., & Hughes, J. T. (1970) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.33.3.338 · Cited by 483
TDP-43 is intercellularly transmitted across axon terminals
Feiler, M. S., Strobel, B., Freischmidt, A., Helferich, A. M., Kappel, J., Brewer, B. M., Li, D., Thal, D. R., Walther, P., Ludolph, A. C., et al. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201504057 · Cited by 329
The cognitive profile of ALS: a systematic review and meta-analysis update
Beeldman, E., Raaphorst, J., Klein Twennaar, M., de Visser, M., Schmand, B. A., & de Haan, R. J. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-310734 · Cited by 313
Nishihira, Y., Tan, C.-F., Onodera, O., Toyoshima, Y., Yamada, M., Morita, T., Nishizawa, M., Kakita, A., & Takahashi, H. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0385-z · Cited by 187
Sasaki, S., & Iwata, M. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12314-4 · Cited by 173
Tartaglia, M. C., Rowe, A., Findlater, K., Orange, J. B., Grace, G., & Strong, M. J. (2007) · Archives of Neurology · doi:10.1001/archneur.64.2.232 · Cited by 151
Review: neuropathology of non-tau frontotemporal lobar degeneration
Neumann, M., & Mackenzie, I. R. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12526 · Cited by 144 · cited 1×
“is known as frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP).(6) Although the sever-”
BackgroundCorticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease
Lindquist, S., Duno, M., Batbayli, M., Puschmann, A., Braendgaard, H., Mardosiene, S., Svenstrup, K., Pinborg, L., Vestergaard, K., Hjermind, L., et al. (2013) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01903.x · Cited by 143
Brettschneider, J., Libon, D. J., Toledo, J. B., Xie, S. X., McCluskey, L., Elman, L., Geser, F., Lee, V. M.-Y., Grossman, M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0932-x · Cited by 142
Cited by
miRNA extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis
Banack, S. A., Dunlop, R. A., Stommel, E. W., Mehta, P., & Cox, P. A. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120396 · Cited by 54
“Equally of concern was the internal variability within ALS as a multifactorial disease with inherent clinicopathological heterogeneity [39,40].”
BackgroundCurrent Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
Jankovic, M., Novakovic, I., Gamil Anwar Dawod, P., Gamil Anwar Dawod, A., Drinic, A., Abdel Motaleb, F. I., Ducic, S., & Nikolic, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189832 · Cited by 36
Bajc Česnik, A., Motaln, H., & Rogelj, B. (2020) · Cells · doi:10.3390/cells9081791 · Cited by 17
Metadata
- Authors
- Takeda, T., Kitagawa, K., & Arai, K.
- Venue
- Neuropathology
- Publisher
- Wiley
- Published
- 2019-12-05
- Volume
- 40
- Issue
- 1
- Pages
- 40-56
- ISSN
- 0919-6544 (ISSN-L)
- 1440-1789
- OpenAlex
- W2991681082
- Cited by
- 46
- References
- 11
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.